FGP
ALNY icon

Freestone Grove Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Freestone Grove Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,412
Closed -$644K – 726
2025
Q3 		$644K Buy
+1,412
New +$575K ﹤0.01% 498

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Freestone Grove Partners's ALNY Position: Q4 2025 in Review

Freestone Grove Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 1,412 shares — an estimated $644K sold.

Freestone Grove Partners first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $644K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Freestone Grove Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 1,412 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $644K.
  • Freestone Grove Partners first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Alnylam Pharmaceuticals position peaked at $644K in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.